TP53 codon 72 Polymorphism and bladder cancer risk: a meta-analysis and emphasis on the role of tumor or smoking status

原文： 2018 年发布于 Oncotarget 37 卷第 09 期 147  浏览量：211次

作者： Zhang L. Wang Y. Qin Z. Q. Li R. Cong R. Ji C. J. Meng X. H. Wang Y. M. Xia J. D. Song N. H.

作者单位： University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: akamat@mdanderson.org. Baylor College of Medicine, Houston, TX, USA. University of Iowa, Iowa City, IA, USA. Analysis Group, Boston, MA, USA. Duke University, Durham, NC, USA. McGill University Health Center, Montreal, QC, Canada. Mayo Clinic, Rochester, MN, USA. Mayo Clinic, Phoenix, AZ, USA. University of Toronto, Toronto, ON, Canada. Vanderbilt University, Nashville, TN, USA. University of Minnesota, Minneapolis, MN, USA. University of Texas Health, San Antonio, TX, USA. NYU Langone Health, New York, NY, USA. Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

归属分类：膀胱肿瘤病因/危险因素证据

DOI： 10.3390/diagnostics11020351

关键词：肌层浸润性膀胱癌保留膀胱手术化疗膀胱切除术荟萃分析

Patient-reported outcome measures (PROMs) are important tools used to understand patient-focused outcomes from care. Various PROMs have been developed for patients with bladder cancer (BC), although the disease's heterogeneity makes selection difficult. Accurate measurement of health-related quality of life (HRQL) can only be achieved if the PROM chosen is 'fit for purpose' (i.e. psychometrically sound). Systematic reviews of psychometric properties are useful for selecting the best PROM for a specific purpose. The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) developed a checklist to improve the selection of health measurement instruments as part of a review process. Our aims were to undertake a systematic review, using the COSMIN criteria, to assess the quality of studies that report the psychometric properties of PROMs used with people with BC and determine the psychometric quality of these PROMs. An electronic search of seven databases including PubMed, MEDLINE and EMBASE (PROSPERO reference CRD42016051974) was undertaken to identify English language publications, published between January 1990 and September 2017 that evaluated psychometric properties of PROMs used in BC research. Two researchers independently screened abstracts and selected full-text papers. Studies were rated on methodological quality using the COSMIN checklist. Overall, 4663 records were screened and 23 studies, reporting outcomes in 3568 patients, were evaluated using the COSMIN checklist. Most PROMs had limited information reported about their psychometric properties. Studies reporting on the Bladder Cancer Index (BCI) and Functional Assessment of Cancer Therapy Vanderbilt Cystectomy Index (FACT-VCI) provided the most detail and these PROMs could be evaluated on the most COSMIN properties. Based on the available evidence, no existing PROM stands out as the most appropriate to measure HRQL in BC populations. This is due to two factors; (i) the heterogeneity of BC and its treatments (ii) no PROM was evaluated on all COSMIN measurement properties due to a lack of validation studies. We suggest future evaluation of generic, cancer generic and BC-specific PROMs to better understand their application with BC populations and propose strategies to help clinicians and researchers.